
Feature|Articles|August 28, 2026
Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance
Author(s)Israel Ortiz
With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical quality levers.
Advertisement
Advertisement
Pharmaceutical manufacturers operate under some of the strictest quality requirements in any industry. Even small deviations in a facility’s environmental conditions can compromise product stability and risk batch losses that can cost manufacturers millions of dollars in lost product, investigations, and production delays. Despite improvements in manufacturing technology, batch failures still occur due to contamination, operator error, and equipment failure. On average, biopharmaceutical manufacturers experience a failure every 40 weeks.
Related to this article

Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.

Dr. Elena Christofides on why cortisol dysregulation may be the hidden reason GLP-1s fail — and what to do when patients don't respond.

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.

HHS confirms permanent directors for CDER and CBER and creates FDA's first-ever Deputy Commissioner for Technology and AI.

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.

Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.

Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
Advertisement
Advertisement

